SG11202109371VA - Antisense oligomers for treatment of conditions and diseases - Google Patents
Antisense oligomers for treatment of conditions and diseasesInfo
- Publication number
- SG11202109371VA SG11202109371VA SG11202109371VA SG11202109371VA SG11202109371VA SG 11202109371V A SG11202109371V A SG 11202109371VA SG 11202109371V A SG11202109371V A SG 11202109371VA SG 11202109371V A SG11202109371V A SG 11202109371VA SG 11202109371V A SG11202109371V A SG 11202109371VA
- Authority
- SG
- Singapore
- Prior art keywords
- diseases
- treatment
- conditions
- antisense oligomers
- antisense
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811511P | 2019-02-27 | 2019-02-27 | |
| PCT/US2020/020175 WO2020176776A1 (en) | 2019-02-27 | 2020-02-27 | Antisense oligomers for treatment of conditions and diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109371VA true SG11202109371VA (en) | 2021-09-29 |
Family
ID=72239261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109371VA SG11202109371VA (en) | 2019-02-27 | 2020-02-27 | Antisense oligomers for treatment of conditions and diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220162605A1 (en) |
| EP (1) | EP3931329A4 (en) |
| JP (1) | JP2022522205A (en) |
| KR (1) | KR20210134003A (en) |
| CN (1) | CN113748209A (en) |
| AU (1) | AU2020227825A1 (en) |
| CA (1) | CA3131591A1 (en) |
| IL (1) | IL285867A (en) |
| SG (1) | SG11202109371VA (en) |
| WO (1) | WO2020176776A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7049248B2 (en) | 2015-12-14 | 2022-04-06 | コールド スプリング ハーバー ラボラトリー | Autosomal dominant mental retardation-5 and antisense oligomers for the treatment of Dravet syndrome |
| AU2018322319B2 (en) | 2017-08-25 | 2021-08-05 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
| EP4069256A4 (en) * | 2019-12-06 | 2023-10-18 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2612180A1 (en) * | 2005-06-16 | 2006-12-21 | Bionomics Limited | Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene |
| CN109112126B (en) * | 2010-06-23 | 2024-06-14 | 库尔纳公司 | Treatment of voltage-gated sodium channel alpha Subunit (SCNA) related diseases by inhibition of natural antisense transcripts of SCNA |
| JP7049248B2 (en) * | 2015-12-14 | 2022-04-06 | コールド スプリング ハーバー ラボラトリー | Autosomal dominant mental retardation-5 and antisense oligomers for the treatment of Dravet syndrome |
| AU2018322319B2 (en) * | 2017-08-25 | 2021-08-05 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
-
2020
- 2020-02-27 CN CN202080031771.0A patent/CN113748209A/en active Pending
- 2020-02-27 EP EP20763143.3A patent/EP3931329A4/en active Pending
- 2020-02-27 KR KR1020217031019A patent/KR20210134003A/en unknown
- 2020-02-27 SG SG11202109371VA patent/SG11202109371VA/en unknown
- 2020-02-27 CA CA3131591A patent/CA3131591A1/en active Pending
- 2020-02-27 WO PCT/US2020/020175 patent/WO2020176776A1/en unknown
- 2020-02-27 AU AU2020227825A patent/AU2020227825A1/en active Pending
- 2020-02-27 JP JP2021550217A patent/JP2022522205A/en active Pending
-
2021
- 2021-08-25 IL IL285867A patent/IL285867A/en unknown
- 2021-08-26 US US17/412,664 patent/US20220162605A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020227825A1 (en) | 2021-10-07 |
| EP3931329A4 (en) | 2023-12-13 |
| WO2020176776A1 (en) | 2020-09-03 |
| CA3131591A1 (en) | 2020-09-03 |
| EP3931329A1 (en) | 2022-01-05 |
| US20220162605A1 (en) | 2022-05-26 |
| KR20210134003A (en) | 2021-11-08 |
| CN113748209A (en) | 2021-12-03 |
| JP2022522205A (en) | 2022-04-14 |
| IL285867A (en) | 2021-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2594767B (en) | Antisense oligomers for treatment of conditions and diseases | |
| GB2584204B (en) | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases | |
| EP4069256A4 (en) | Antisense oligomers for treatment of conditions and diseases | |
| IL285867A (en) | Antisense oligomers for treatment of conditions and diseases | |
| IL288574A (en) | Oligonucleotides and methods of use for treating neurological diseases | |
| IL284700A (en) | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors | |
| IL291362A (en) | Treatment of syngap1 encephalopathy | |
| GB202005231D0 (en) | Method of mimimising patient risk | |
| EP4127174A4 (en) | Antisense oligomers for treatment of disease | |
| IL291146A (en) | Treatment of hidradenitis with jak inhibitors | |
| GB201907305D0 (en) | Treatment of conditions | |
| IL268111A (en) | Methods of treating pain | |
| GB201905810D0 (en) | Method of treatment | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
| GB201904764D0 (en) | Treatment of ophthalmological conditions | |
| EP4003283C0 (en) | Treatment of inflammatory skin conditions | |
| GB201917253D0 (en) | Treatment of conditions | |
| ZA201904327B (en) | Treatment of skin conditions | |
| GB201909438D0 (en) | Treatment of diseases | |
| IL290983A (en) | Methods of treatment | |
| AU2020901278A0 (en) | Antisense Oligomers for Treatment of Disease | |
| AU2020900883A0 (en) | Antisense Oligomers for Treatment of Disease | |
| GB201815000D0 (en) | Treatment of hypothroidism and related conditions | |
| GB201918853D0 (en) | Methods of treatment | |
| GB202101251D0 (en) | Treatment of conditions |